Medical Practice S.R.L.
- Address
- Ground Floor, Strada Ingusta 2, 410001 Oradea, Romania
Medical Practice S.R.L. - Cardiometabolic Disease Research Center
Medical Practice S.R.L. is a specialized clinical research facility focused on advancing treatment strategies for cardiometabolic conditions. The center conducts pivotal studies in metabolic and cardiovascular disease prevention, with particular expertise in optimizing therapeutic approaches for high-risk patient populations.
- Type 2 diabetes management and insulin optimization strategies
- Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
- Novel lipid-lowering therapies and cardiovascular risk reduction
The research portfolio includes innovative trials examining combination therapy approaches in type 2 diabetes, such as semaglutide with dose-reduced insulin regimens, as well as landmark cardiovascular prevention studies evaluating inclisiran for reducing major adverse cardiovascular events (MACE) in high-risk primary prevention patients. The center's work contributes to evidence-based strategies for glycemic control, cardiovascular risk mitigation, and improved outcomes in patients with metabolic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Practice S.R.L.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial | Eli Lilly & Co. | Phase III | Not Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.